HAIs (healthcare-associated infections) evolution explains UK C diff (Clostridium difficile) testing focus
This article was originally published in Clinica
UK efforts to tackle methicillin-resistant Staphylococcus aureus (MRSA) appear to be succeeding in reducing bloodstream healthcare-associated infection (HAI) rates, but a further jump in cases of Clostridium difficile - a non-bloodstream HAI - explains the current drive to further tighten surveillance (see related story).
You may also be interested in...
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Execs On The Move: New Global Comms Boss At Siemens; CRH CEO Now Also Chair; New CEO At ChroniSense Medical
German multinational firm Siemens picks a global communications head; CRH Medical CEO also takes on chairmanship; ChroniSense Medical, a developer of medical monitoring devices, hires a new CEO; and more.